Lusine Harutyunyan, Hematologist, R1 Researcher at Yeolyan Hematology and Oncology Center, shared on LinkedIn:
“One more case report has been reviewed.
Please read the story of a patient with stage III non-germinal center DLBCL who underwent CAR-T therapy following chemotherapy and subsequently developed treatment-related MDS, rapidly progressing to AML within two months. The key message is clear: persistent post-CAR-T cytopenia may represent an early manifestation of an underlying therapy-related myeloid neoplasm (t-MN) rather than transient hematotoxicity, highlighting the need for prompt diagnosis and appropriate clinical attention.
This case report opens an important discussion for future research.”
Title: Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report
Authors: Longmei Chen, Wanchao Liu
Other articles about AML on OncoDaily.